Andreas Varkaris

1.5k total citations
46 papers, 836 citations indexed

About

Andreas Varkaris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Andreas Varkaris has authored 46 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Andreas Varkaris's work include Prostate Cancer Treatment and Research (12 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Advanced Breast Cancer Therapies (6 papers). Andreas Varkaris is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Advanced Breast Cancer Therapies (6 papers). Andreas Varkaris collaborates with scholars based in United States, Greece and Spain. Andreas Varkaris's co-authors include Gary E. Gallick, Paul G. Corn, Sanchaika Gaur, Christopher J. Logothetis, Αναστασία Κατσιαμπούρα, Nila U. Parikh, Jian H. Song, Farshid Dayyani, John C. Araujo and Steven P. Balk and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Andreas Varkaris

44 papers receiving 823 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Varkaris United States 17 393 331 327 253 70 46 836
Ken Suzawa Japan 19 483 1.2× 504 1.5× 565 1.7× 282 1.1× 65 0.9× 80 1.1k
François Ringeisen France 14 517 1.3× 373 1.1× 305 0.9× 175 0.7× 38 0.5× 33 899
Haruyoshi Tanaka Japan 20 496 1.3× 352 1.1× 314 1.0× 179 0.7× 24 0.3× 52 947
Erwan Pencreach France 17 323 0.8× 350 1.1× 200 0.6× 248 1.0× 27 0.4× 35 797
Oriol Arpí Spain 15 359 0.9× 376 1.1× 126 0.4× 149 0.6× 64 0.9× 24 710
Stephanie Petrillo Canada 18 394 1.0× 293 0.9× 118 0.4× 216 0.9× 64 0.9× 38 794
David Molkentine United States 16 371 0.9× 357 1.1× 186 0.6× 125 0.5× 67 1.0× 30 708
Liru He China 18 410 1.0× 159 0.5× 263 0.8× 197 0.8× 50 0.7× 54 758

Countries citing papers authored by Andreas Varkaris

Since Specialization
Citations

This map shows the geographic impact of Andreas Varkaris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Varkaris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Varkaris more than expected).

Fields of papers citing papers by Andreas Varkaris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Varkaris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Varkaris. The network helps show where Andreas Varkaris may publish in the future.

Co-authorship network of co-authors of Andreas Varkaris

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Varkaris. A scholar is included among the top collaborators of Andreas Varkaris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Varkaris. Andreas Varkaris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nouri, Mannan, Andreas Varkaris, Maya Ridinger, et al.. (2024). AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. Molecular Cancer Therapeutics. 23(10). 1404–1417. 3 indexed citations
2.
Varkaris, Andreas & Zdravka Medarova. (2024). 383P Clinical experience with TTX-MC138: A first-in-class therapy against metastatic cancer. Annals of Oncology. 35. S379–S379. 2 indexed citations
3.
Hollebecque, Antoine, Efrat Dotan, Chih‐Yi Liao, et al.. (2024). 58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study. European Journal of Cancer. 211. 114585–114585. 1 indexed citations
4.
5.
Wang, Keshan, Fen Ma, Seiji Arai, et al.. (2023). WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Research. 83(7). 1016–1030. 26 indexed citations
6.
Varkaris, Andreas, Komal Jhaveri, Cesar A. Perez, et al.. (2023). Abstract CT017: Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial. Cancer Research. 83(8_Supplement). CT017–CT017. 5 indexed citations
7.
Patterson, Jesse C., Andreas Varkaris, Peter J.P. Croucher, et al.. (2022). Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. 83(2). 219–238. 12 indexed citations
8.
Arai, Seiji, Andreas Varkaris, Mannan Nouri, et al.. (2020). MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. eLife. 9. 37 indexed citations
9.
Viray, Hollis, Andreas Varkaris, Masanori Fujii, et al.. (2020). EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports. 1(3). 100051–100051. 53 indexed citations
10.
Thamcharoen, Natanong, et al.. (2019). Unusual Presentation of Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Patient. SHILAP Revista de lepidopterología. 2019. 1–4. 8 indexed citations
11.
Sehgal, Kartik, Andreas Varkaris, Paul A. VanderLaan, Deepa Rangachari, & Daniel B. Costa. (2019). P1.04-73 Small Cell Transformation of Non-Small Cell Lung Cancer (NSCLC) on Immune Checkpoint Inhibitors: Case Report and Literature Review. Journal of Thoracic Oncology. 14(10). S470–S471.
12.
Varkaris, Andreas, Wenxin Xu, Roger B. Davis, Brian C. Healy, & David F. McDermott. (2019). Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(3). 179–184.e3. 8 indexed citations
13.
Varkaris, Andreas, Αναστασία Κατσιαμπούρα, Jennifer S. Davis, et al.. (2019). Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. British Journal of Cancer. 120(3). 340–345. 28 indexed citations
14.
Κατσιαμπούρα, Αναστασία, et al.. (2018). Prediction of dysnatremias in critically ill patients based on the law of conservation of mass. Comparison of existing formulae. PLoS ONE. 13(11). e0207603–e0207603. 6 indexed citations
15.
Κατσιαμπούρα, Αναστασία, Kanwal Raghav, Zhi-Qin Jiang, et al.. (2017). Modeling of Patient-Derived Xenografts in Colorectal Cancer. Molecular Cancer Therapeutics. 16(7). 1435–1442. 38 indexed citations
16.
Varkaris, Andreas, Paul G. Corn, Nila U. Parikh, et al.. (2015). Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clinical Cancer Research. 22(1). 107–121. 37 indexed citations
17.
Lee, Yu-Chen, Song-Chang Lin, Guoyu Yu, et al.. (2015). Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Research. 75(22). 4949–4959. 36 indexed citations
18.
Varkaris, Andreas, Αναστασία Κατσιαμπούρα, John C. Araujo, Gary E. Gallick, & Paul G. Corn. (2014). Src signaling pathways in prostate cancer. Cancer and Metastasis Reviews. 33(2-3). 595–606. 82 indexed citations
19.
Dayyani, Farshid, Andreas Varkaris, John C. Araujo, et al.. (2013). Increased serum insulin‐like growth factor‐1 levels are associated with prolonged response to dasatinib‐based regimens in metastatic prostate cancer. The Prostate. 73(9). 979–985. 9 indexed citations
20.
Bournakis, Evangelos, Eleni Efstathiou, Andreas Varkaris, et al.. (2011). Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer. Urology. 77(3). 682–687. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ken Suzawa Breakdown of academic impact, for papers by François Ringeisen Breakdown of academic impact, for papers by Haruyoshi Tanaka Breakdown of academic impact, for papers by Erwan Pencreach Breakdown of academic impact, for papers by Oriol Arpí Breakdown of academic impact, for papers by Stephanie Petrillo Breakdown of academic impact, for papers by David Molkentine Breakdown of academic impact, for papers by Liru He
Rankless by CCL
2026